Table 3 Pathway analysis of biomarkers that distinguish 14 class compounds

Mitotic roles of polo-like kinase

11.6

1.45E-01

KIF23, CCNB1, ESPL1, CDC20, PTTG1, PRC1, CCNB2, PLK1, CDC2

Cell Cycle: G2/M DNA damage checkpoint regulation

6.17

1.16E-01

CCNB1, TOP2A, CCNB2, PLK1, CDC2

ATM signaling

4.16

7.55E-02

RAD51, CCNB1, CCNB2, CDC2

Nicotinate and nicotinamide metabolism

3.03

2.94E-02

NEK2, PLK1, TTK, CDC2

Inositol phosphate metabolism

2.57

2.27E-02

NEK2, PLK1, TTK, CDC2

Sonic hedgehog signaling

2.15

6.06E-02

CCNB1, CDC2

Pancreatic adenocarcinoma signaling

2

2.59E-02

RAD51, CCNE1, BIRC5

Hereditary breast cancer signaling

1.85

2.33E-02

RAD51, CCNB1, CDC2

Role of BRCA1 in DNA damage response

1.62

3.28E-02

RAD51, PLK1